men may have contributed to improving sexual function. Changes in erectile function and body weight were accompanied by changes in quality of life. Disclosure: Work supported by industry: yes, by Bayer AG (industry funding only - investigator initiated and executed study). 098 SEXUAL LIFE SATISFACTION RELATED TO ERECTILE FUNCTION ACROSS DIFFERENT AGES Capogrosso, P. 1 ; Ventimiglia, E. 1 ; Boeri, L. 2 ; Cazzaniga, W. 1 ; Pederzoli, F. 1 ; Chierigo, F. 1 ; Frego, N. 1 ; Moretti, D. 1 ; Deho’, F. 1 ; Gaboardi, F. 1 ; Montanari, E. 2 ; Mirone, V. 3 ; Montorsi, F. 1 ; Salonia, A. 1 1 San Raffaele Hospital - University Vita-Salute San Raffaele, Italy; 2 Fondazione Ca’ Granda e Maggiore Hospital, University of Milan, Italy; 3 University of Naples Federico II, Italy Objective: To assess changes in terms of overall satisfaction (OS) and intercourse satisfaction (IS) domains of the International Index of Erectile Function (IIEF) according to the IIEF-EF domain score across different patients ages. Materials and Methods: Complete data were available for 1010 patients visiting a single academic center in 2005-2017 for erectile dysfunction (ED). Every patient was asked to complete the IIEF questionnaire at first assessment. Patients were catego- rized as young (<50 yrs), middle-aged (50-64) and old (>¼65), respectively. Similarly, patients were categorized as having severe (IIEF-EF<11), moderate (IIEF-EF 11-21), mild (IIEF-EF 22-25) ED or normal EF (IIEF-EF>26) according to the IIEF-EF score, respectively. The one-way analysis of variance tested the mean OS and IS domain scores according to the IIEF-EF categories and within age groups. Linear regression analyses tested the as- sociation of both IIEF-OS and IIEF-IS scores with patients’ age and IIEF-EF score. Results: Overall, 499 (49%), 366 (36%) and 147 (15%) pa- tients were categorized as young, middle-aged and old, respec- tively. Of all, 32% (327), 28% (281) and 20% (200) of patients had severe, moderate and mild ED, respectively. At linear regression analyses, both age and EF score were linearly associ- ated with either OS and IS score, showing that the older the patient, the higher the increase in the satisfaction scores for the same increase in the EF score (p<0.01). Among old men, mean OS and IS scores were not significantly different between those with mild ED and normal EF (OS: 8.4 vs. 8.4; IS: 10.7 vs. 11.5; p>0.5). Likewise, the increase in the IIEF-EF score was not associated with a significant increase of the OS and IS domain scores among old patients with mild ED (p>0.2). Conversely, both young and middle-aged men showed a linear increase in the satisfaction scores associated with the increase of IIEF-EF score, across all ED categories (p<0.01). Conclusions: Patients’ perception of EF-related sexual satisfaction changes throughout aging. Our findings suggest that the older the patient the higher the increase of overall and intercourse satisfac- tion for any EF increase; however, patients of 65 years or older with mild ED may not necessarily benefit from treatment since a further improvement in their sexual satisfaction is not expected. Disclosure: Work supported by industry: no. 099 ERECTILE FUNCTION IMPROVES IN HYPOGONADAL MEN WITH TYPE 2 DIABETES UNDER LONG-TERM TESTOSTERONE THERAPY: REAL-WORLD EVIDENCE FROM A UROLOGICAL REGISTRY STUDY Saad, F. 1 ; Haider, K.S. 2 ; Doros, G. 3 ; Traish, A. 4 ; Haider, A. 2 1 Bayer AG, Germany; 2 Private Urology Practice, Germany; 3 Boston University School of Public Health, USA; 4 Boston University School of Medicine, USA Objectives: Erectile dysfunction affects the majority of patients with type 2 diabetes (T2DM) and remains difficult to treat. Hypogonadism is highly prevalent in men with T2DM. We investigated effects of testosterone therapy (TTh) in hypogonadal men with T2DM in a urological office. Material and Methods: 133 men with T2DM, testosterone 12.1 nmol/L and hypogonadal symptoms received testosterone undecanoate 1000 mg every 3 months following an initial 6- week interval for up to 10 years. 153 hypogonadal men with T2DM decided against TTh and served as controls. Measure- ments were performed 1-4 times a year and included IIEF-EF (5+1, maximum score: 30), fasting glucose, HbA 1c , insulin, and HOMA-IR. Differences between groups were estimated and adjusted for age and metabolic syndrome parameters to account for baseline differences between groups. Results: Mean age: 63±5 years (T-group: 62±5, CTRL: 64±5). IIEF-EF increased from 18.3±5.4 to 27±2 in the T-group and declined from 19.8±3.3 to 9±2.1 in CTRL, between-group dif- ference: 19.7 (p<0.0001 for all). Fasting glucose decreased from 7.6±1.1 to 5.3±0.1 mmol/L in the T-group and increased from 6.2±0.6 to 6.9±1.0 mmol/L in CTRL, between-group difference: -2.2 mmol/L (p<0.0001 for all). HbA 1c decreased from 8.8±0.9 to 5.9±0.3% at 10 years in the T-group and increased from 7.7±0.6 to 9.5±0.9% in CTRL, between-group difference: -4.6% (p<0.0001 for all). Fasting insulin decreased from 29.6±4.2 to 15±4.8 mU/mL in the T-group and increased in CTRL from 26.5±2.6 to 37 mU/mL, between-group difference: -23.1 mU/mL (p<0.0001 for all). HOMA-IR decreased from 10.2±2.0 to 3.6±1.2 in the T-group and increased in CTRL from 7.4±1.4 to 11.4, between-group difference: -9.4 mmol/L (p<0.0001 for all). At baseline, 54 patients in the T-group received insulin at a mean dose of 32.4±12.1 units/day. Mean dose requirement declined to 20.6±11.3 units. In CTRL, 55 patients received insulin at a mean dose of 29.4±5 units/day with an increase of mean dose requirement to 39.5±7.2 units, estimated adjusted difference between groups: -25.7 units/day (p<0.0001). Conclusions: Erectile function in men with T2DM improved sustainably under long-term TTh and progressed in untreated hypogonadal controls. Testosterone should be measured routinely and TTh offered to men with T2DM when indicated, J Sex Med 2018;15:S123eS407 Proceedings of the 21st World Meeting on Sexual Medicine S169 Downloaded from https://academic.oup.com/jsm/article/15/Supplement_3/S169/7011951 by guest on 02 February 2023